Trials / Recruiting
RecruitingNCT06350955
IV Iron-induced Hypophosphatemia After RYGB
Intravenous Iron-induced Hypophosphatemia in Patients With Roux-en-Y Gastric Bypass: a Single-blind, Randomized Clinical Trial Comparing Iron Isomaltoside (Monofer®) and Ferric Carboxymaltose (Ferinject®)
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- Sponsor
- Lucie Favre · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to compare the incidence of hypophosphatemia in RYGB patients treated with intravenous (IV) single dose of iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iron isomaltoside | single dose of 500 mg iron isomaltoside |
| DRUG | Iron Carboxymaltose | single dose of 500 mg ferric carboxymaltose |
Timeline
- Start date
- 2024-05-02
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2024-04-08
- Last updated
- 2024-08-20
Locations
1 site across 1 country: Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06350955. Inclusion in this directory is not an endorsement.